- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03607422
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, and a 30-day follow-up visit.
Participants who meet eligibility criteria in the main study will be randomized in a 1:1:1 ratio to receive a daily oral dose of upadacitinib 30 mg or upadacitinib 15 mg or matching placebo. Upon completion of enrollment of a minimum of 810 participants in the main study, a supplemental study will continue to enroll adolescents (adolescent sub-study) until a total of 180 adolescent participants are enrolled overall (main study + adolescent sub-study).
Randomization in the main study will be stratified by baseline disease severity (validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (United States [US]/Puerto Rico/Canada, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the adolescent sub-study will be stratified by baseline disease severity (moderate [vIGA-AD = 3] vs. severe [vIGA-AD = 4]) and by geographic region (US/Puerto Rico/Canada and Other).
At Week 16 of the main study and the adolescent sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period. In the main study the re-randomization at Week 16 will be stratified by Week 16 50% improvement in Eczema Area and Severity Index [EASI 50] responder [Yes/No], geographic region [US/Puerto Rico/Canada, and other], and age group [adolescent/adult]. For the adolescent sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other). Participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose.
Starting at the Week 4 visit, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary.
The Primary Analysis for the main study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the main study and the adolescent sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Expanded Access
Contacts and Locations
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- The Skin Hospital /ID# 217846
-
-
Queensland
-
Benowa, Queensland, Australia, 4217
- The Skin Centre /ID# 205922
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Box Hill Hospital /ID# 206023
-
Clayton, Victoria, Australia, 3168
- Monash Children's Hospital /ID# 217917
-
East Melbourne, Victoria, Australia, 3002
- Sinclair Dermatology /ID# 217791
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital /ID# 205919
-
Parkville, Victoria, Australia, 3052
- Murdoch Children's Research Institute /ID# 205667
-
-
-
-
-
Salzburg, Austria, 5020
- Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 208281
-
-
Niederoesterreich
-
Sankt Poelten, Niederoesterreich, Austria, 3100
- Universitaetsklinikum St. Poelten /ID# 206909
-
-
Oberoesterreich
-
Linz, Oberoesterreich, Austria, 4010
- Ordensklinikum Linz GmbH Elisabethinen /ID# 206573
-
-
Wien
-
Vienna, Wien, Austria, 1220
- Klinik Donaustadt /ID# 206572
-
-
-
-
-
Liege, Belgium, 4000
- Centre Hospitalier Universitaire du Sart Tilman CHU de Liege /ID# 204938
-
-
Bruxelles-Capitale
-
Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium, 1200
- UCL Saint-Luc /ID# 205537
-
-
Oost-Vlaanderen
-
Gent, Oost-Vlaanderen, Belgium, 9000
- UZ Gent /ID# 205181
-
-
-
-
-
Sofia, Bulgaria, 1000
- Medical center Sveti Panteleimon /ID# 210414
-
Sofia, Bulgaria, 1407
- Acibadem City Clinic Tokuda University Hospital EAD /ID# 205292
-
Sofia, Bulgaria, 1606
- Military Medical Academy Multiprofile Hospital /ID# 205291
-
Sofia, Bulgaria, 1632
- Medical complex Doverie /ID# 211289
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T5K 1X3
- Stratica Medical /ID# 205415
-
Edmonton, Alberta, Canada, T6G 1C3
- Alberta DermaSurgery Centre /ID# 205422
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E8
- UBC Department of Dermatology and Skin Science The Skin Care Centre /ID# 207837
-
Vancouver, British Columbia, Canada, V6H 4E1
- Pacific Derm /ID# 206797
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1E 1V4
- Skin Care Studio /ID# 205420
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 7G1
- SimcoDerm Medical and Surgical Dermatology Center /ID# 206333
-
Etobicoke, Ontario, Canada, M8X 1Y9
- Kingsway Clinical Research /ID# 206005
-
Guelph, Ontario, Canada, N1L 0B7
- Dr. Dusan Sajic Medicine Professional Corporation /ID# 206890
-
London, Ontario, Canada, N6A 3H7
- The Guenther Dermatology Research Centre /ID# 206772
-
Mississauga, Ontario, Canada, L5H 1G9
- DermEdge Research Inc. /ID# 206036
-
Newmarket, Ontario, Canada, L3Y 5G8
- Dr. S.K. Siddha Medicine Professional Corporation /ID# 207138
-
Niagara Falls, Ontario, Canada, L2H 1H5
- Allergy Research Canada Inc. /ID# 213547
-
Sudbury, Ontario, Canada, P3C 1X8
- Dr. Lyne Giroux Medicine Professional Corporation /ID# 206771
-
Toronto, Ontario, Canada, M2M 4J5
- Niakosari Medicine Professional Corporation /ID# 206004
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7K 0H6
- Skinsense Medical Research /ID# 206873
-
-
-
-
Grad Zagreb
-
Zagreb, Grad Zagreb, Croatia, 10000
- DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 205429
-
Zagreb, Grad Zagreb, Croatia, 10000
- Djecja bolnica Srebrnjak /ID# 205926
-
Zagreb, Grad Zagreb, Croatia, 10000
- Poliklinika Vlatka Cavka d.o.o. /ID# 211126
-
-
Zagrebacka Zupanija
-
Ivanic-Grad, Zagrebacka Zupanija, Croatia, 10310
- Naftalan - Specijalna bolnica za medicinsku rehabilitaciju /ID# 203448
-
-
-
-
-
Plzen, Czechia, 305 99
- Fakultni nemocnice Plzen /ID# 205096
-
Praha, Czechia, 110 00
- Sanatorium profesora Arenbergera /ID# 205098
-
Praha, Czechia, 128 08
- Vseobecna fakultni nemocnice v Praze /ID# 205201
-
Praha, Czechia, 150 06
- Fakultni Nemocnice v Motole /ID# 218192
-
Usti nad Labem, Czechia, 400 11
- Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o. z. /ID# 205097
-
-
-
-
Midtjylland
-
Aarhus N, Midtjylland, Denmark, 8200
- Aarhus University Hospital /ID# 205524
-
-
Sjælland
-
Roskilde, Sjælland, Denmark, 4000
- Sjællands Universitetshospital /ID# 205960
-
-
-
-
-
Bordeaux, France, 33075
- Hopital Saint-Andre /ID# 206554
-
Brest, France, 29200
- CHRU de Brest - Hopital Morvan /ID# 206555
-
Lorient, France, 56322
- C.H. de Bretagne Sud /ID# 206910
-
Paris, France, 75010
- AP-HP - Hopital Saint-Louis /ID# 206552
-
-
Ile-de-France
-
Antony, Ile-de-France, France, 92160
- Hopital Prive d'Antony /ID# 206553
-
-
-
-
-
Darmstadt, Germany, 64283
- Klinikum Darmstadt /ID# 207483
-
Dresden, Germany, 01307
- Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 205767
-
Hamburg, Germany, 20246
- Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 207982
-
Mahlow, Germany, 15831
- Dermatologische Gemeinschaftspraxis Mahlow /ID# 205765
-
Simmern, Germany, 55469
- Haut- und Laserzentrum Hunsrück /ID# 205768
-
Witten, Germany, 58453
- Hautarztpraxis Dr. med. Matthias Hoffmann /ID# 205766
-
Wuppertal, Germany, 42287
- CentroDerm GmbH /ID# 206861
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
- Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 206658
-
-
-
-
Attiki
-
Athens, Attiki, Greece, 11525
- 251 Airforce General Hospital /ID# 205841
-
Athens, Attiki, Greece, 11525
- 401 GSNA - 401 Army General Hospital /ID# 205352
-
Athens, Attiki, Greece, 16121
- General Hospital Andreas Syggros /ID# 204527
-
-
Thessaloniki
-
Stavroupoli (Thessalonikis), Thessaloniki, Greece, 55536
- Papageorgiou General Hospital Thessaloniki /ID# 204526
-
-
-
-
-
Budapest, Hungary, 1033
- Clinexpert Kft /ID# 211246
-
Budapest, Hungary, 1036
- Synexus Magyarorszag Kft. /ID# 206008
-
Pecs, Hungary, 7624
- Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 205085
-
-
Borsod-Abauj-Zemplen
-
Miskolc, Borsod-Abauj-Zemplen, Hungary, 3526
- Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 218072
-
-
Heves
-
Gyöngyös, Heves, Hungary, 3200
- Bugat Pal Korhaz /ID# 211247
-
-
Somogy
-
Kaposvár, Somogy, Hungary, 7400
- Somogy Megyei Kaposi Mor Oktato Korhaz /ID# 205611
-
-
Veszprem
-
Balatonfured, Veszprem, Hungary, 8230
- Drug Research Center /ID# 217855
-
-
-
-
-
Cork, Ireland, T12 X23H
- South Infirmary Victoria University Hospital /ID# 204265
-
Galway, Ireland, H91 YR71
- University Hospital Galway /ID# 209965
-
Waterford, Ireland, X91 ER8E
- University Hospital Waterford /ID# 204266
-
-
Dublin
-
Dublin 8, Dublin, Ireland, D08 NHY1
- St James Hospital /ID# 204264
-
-
-
-
-
Brescia, Italy, 25123
- ASST Spedali civili di Brescia /ID# 205927
-
Cagliari, Italy, 09124
- Azienda Ospedaliero Universitaria di Cagliari- Presidio Ospedaliero /ID# 205168
-
L'Aquila, Italy, 67100
- Presidio Ospedaliero San Salvatore /ID# 205167
-
Modena, Italy, 41124
- Azienda Ospedaliero-Universitaria di Modena /ID# 205169
-
-
Lazio
-
Rome, Lazio, Italy, 00144
- IRCCS Istituti Fisioterapici Ospitalieri-Istituto Dermatologico San Gallicano /ID# 205986
-
Rome, Lazio, Italy, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 205987
-
-
-
-
-
Incheon, Korea, Republic of, 21431
- The Catholic University of Korea Incheon St.Mary's Hospital /ID# 206529
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital /ID# 206396
-
Seoul, Korea, Republic of, 06973
- Chung-Ang University Hostipal /ID# 206397
-
Seoul, Korea, Republic of, 07441
- Hallym University Kangnam Sacred Heart Hospital /ID# 206343
-
-
Gyeonggido
-
Ansan, Gyeonggido, Korea, Republic of, 15355
- Korea University Ansan Hospital /ID# 206342
-
Buncheon, Gyeonggido, Korea, Republic of, 14584
- SoonChunHyang University Buchon Hospital /ID# 206391
-
Suwon, Gyeonggido, Korea, Republic of, 16499
- Ajou University Hospital /ID# 206341
-
-
-
-
-
Alkmaar, Netherlands, 1817 MS
- Centrum Oosterwal /ID# 209640
-
Delft, Netherlands, 2625 AD
- Reinier de Graaf /ID# 205811
-
Groningen, Netherlands, 9713 GZ
- Universitair Medisch Centrum Groningen /ID# 205162
-
-
Noord-Brabant
-
Bergen op Zoom, Noord-Brabant, Netherlands, 4624 VT
- Bravis Ziekenhuis /ID# 206676
-
-
-
-
Auckland
-
Epsom, Auckland, New Zealand, 1051
- Greenlane Clinical Centre /ID# 205664
-
-
-
-
-
Braga, Portugal, 4710-243
- CCA Braga - Hospital de Braga /ID# 205854
-
Leiria, Portugal, 2410-197
- Centro Hospitalar de Leiria, EPE /ID# 209906
-
Lisboa, Portugal, 1649-035
- Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 205839
-
Lisboa, Portugal, 1998-018
- Hospital CUF Descobertas /ID# 205431
-
Porto, Portugal, 4050
- CHP, EPE- Hospital Geral de Sa /ID# 205187
-
Porto, Portugal, 4200-319
- Centro Hospitalar Universitario de Sao Joao, EPE /ID# 205679
-
-
-
-
-
Singapore, Singapore, 119074
- National University Hospital /ID# 205224
-
Singapore, Singapore, 169608
- Singapore General Hospital /ID# 205225
-
Singapore, Singapore, 229899
- KK Women's & Children Hospital /ID# 206693
-
Singapore, Singapore, 529889
- Changi General Hospital /ID# 205223
-
-
Central Singapore
-
Singapore, Central Singapore, Singapore, 308205
- National Skin Centre /ID# 205222
-
-
-
-
-
Barcelona, Spain, 08003
- Hospital Parc de Salut del Mar /ID# 204709
-
Barcelona, Spain, 08036
- Hospital Clinic de Barcelona /ID# 210564
-
Cordoba, Spain, 14004
- Hospital Universitario Reina Sofia /ID# 204712
-
Granada, Spain, 18016
- Hospital Campus de la Salud /ID# 205544
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon /ID# 204380
-
Madrid, Spain, 28009
- Hospital Infantil Universitario Nino Jesus /ID# 210437
-
Madrid, Spain, 28031
- Hospital Universitario Infanta Leonor /ID# 204710
-
Valencia, Spain, 46014
- Hospital General Universitario de Valencia /ID# 210565
-
-
Asturias
-
Mieres, Asturias, Spain, 33611
- Hospital Vital Alvarez Buylla /ID# 205770
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spain, 08950
- Hospital Sant Joan de Deu /ID# 218047
-
-
-
-
-
New Taipei City, Taiwan, 23561
- Taipei Medical University Shuang Ho Hospital /ID# 204804
-
Taichung, Taiwan, 40201
- Chung Shan Medical University Hospital /ID# 205092
-
Taipei City, Taiwan, 100
- National Taiwan University Hospital /ID# 204803
-
Taoyuan City, Taiwan, 333
- Linkou Chang Gung Memorial Ho /ID# 204783
-
-
-
-
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 204993
-
Plymouth, United Kingdom, PL6 8DH
- University Hospital Plymouth NHS Trust /ID# 204649
-
-
Hampshire
-
Southampton, Hampshire, United Kingdom, SO16 6YD
- University Hospital Southampton NHS Foundation Trust /ID# 205711
-
-
Harrow
-
Middlesex, Harrow, United Kingdom, HA1 3UJ
- Northwick Park Hospital /ID# 205250
-
-
London, City Of
-
London, London, City Of, United Kingdom, E1 2ES
- Barts Health NHS Trust /ID# 206491
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Total Skin and Beauty Derm Ctr /ID# 205129
-
-
Arizona
-
Phoenix, Arizona, United States, 85006-2722
- Medical Dermatology Specialist /ID# 205516
-
Phoenix, Arizona, United States, 85053-4061
- Arizona Research Center, Inc. /ID# 205795
-
-
Arkansas
-
Bryant, Arkansas, United States, 72022-7514
- The Dermatology Clinic of Arkansas /ID# 218749
-
North Little Rock, Arkansas, United States, 72117
- Arkansas Research Trials /ID# 218469
-
-
California
-
Encino, California, United States, 91436
- Encino Research Center /ID# 207472
-
Irvine, California, United States, 92697-1385
- University of California Irvine /ID# 205136
-
Long Beach, California, United States, 90806-2325
- Ark Clinical Research /ID# 218193
-
Los Angeles, California, United States, 90033
- Keck School of Medicine of USC /ID# 206971
-
Los Angeles, California, United States, 90056
- Wallace Medical Group /ID# 205701
-
Orange, California, United States, 92868
- Child Hosp of Orange County,CA /ID# 205735
-
Palm Springs, California, United States, 92262
- Palmtree Clinical Research Inc. /Id# 206184
-
San Diego, California, United States, 92123
- Rady Children's Hospital San Diego /ID# 208244
-
Santa Ana, California, United States, 92701
- Southern California Derma. Inc /ID# 205734
-
-
Colorado
-
Lafayette, Colorado, United States, 80026
- Innovative Clinical Research - Lafayette /ID# 208400
-
-
Connecticut
-
Bridgeport, Connecticut, United States, 06606-1827
- New England Research Associates, LLC /ID# 206896
-
-
Florida
-
Aventura, Florida, United States, 33180
- Ideal Clinical Research Inc. /ID# 209880
-
Boca Raton, Florida, United States, 33486-2269
- Skin Care Research, LLC /ID# 207099
-
Brandon, Florida, United States, 33511-5335
- Midflorida Clinical Research, Inc. /ID# 213700
-
Clearwater, Florida, United States, 33765
- Clinical Research of West Florida, Inc /ID# 206146
-
Doral, Florida, United States, 33122-1902
- Revival Research /ID# 208383
-
Doral, Florida, United States, 33166
- Universal Axon Clinical Research /ID# 213703
-
Miami, Florida, United States, 33014
- Lakes Research, LLC /ID# 209156
-
Miami, Florida, United States, 33176
- Miami Dade Medical Research Institute /ID# 209413
-
Miami Lakes, Florida, United States, 33014-2490
- Savin Medical Group, LLC /ID# 206902
-
Miami Lakes, Florida, United States, 33016-1842
- Floridian Clinical Research /ID# 207433
-
Naples, Florida, United States, 34102-5430
- Advanced Research for Health Improvement /ID# 217987
-
Naples, Florida, United States, 34102-5430
- Advanced Research for Health Improvement /ID# 218003
-
Ormond Beach, Florida, United States, 32174-6302
- Complete Health Research /ID# 213459
-
Sunrise, Florida, United States, 33351-7311
- Precision Clinical Research /ID# 207364
-
Tampa, Florida, United States, 33607
- Clinical Research Trials of Florida, Inc. /ID# 206840
-
Tampa, Florida, United States, 33613-1244
- ForCare Clinical Research /ID# 205120
-
-
Georgia
-
Albany, Georgia, United States, 31707-1282
- Georgia Pollens Clinical Research Centers, Inc /ID# 218567
-
Marietta, Georgia, United States, 30060-1047
- Marietta Dermatology Clinical Research /ID# 210317
-
Sandy Springs, Georgia, United States, 30342
- Agile Clinical Research Trials /ID# 218080
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Treasure Valley Medical Research /ID# 210298
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- Great Lakes Clinical Trials /ID# 205830
-
Gurnee, Illinois, United States, 60031-3393
- Ashira Dermatology /ID# 205512
-
Gurnee, Illinois, United States, 60031
- Clinical Investigation Specialists, Inc. /ID# 206898
-
Skokie, Illinois, United States, 60077
- Northshore University Health System Dermatology Clinical Trials Unit /ID# 205135
-
-
Indiana
-
Crown Point, Indiana, United States, 46307
- Raga Clinical Studies, LLC. /ID# 206749
-
-
Kansas
-
Hutchinson, Kansas, United States, 67502-1131
- Hutchinson Clinic /ID# 205970
-
-
Maryland
-
Towson, Maryland, United States, 21204
- Continental Clinical Solutions /ID# 210327
-
-
Massachusetts
-
Quincy, Massachusetts, United States, 02169
- Beacon Clinical Research, LLC /ID# 206894
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48103
- David Fivenson, MD, PLC /ID# 206903
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 206895
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68505-2343
- Allergy, Asthma & Immunology Associates, PC /ID# 218169
-
Omaha, Nebraska, United States, 68144
- Skin Specialists, PC /ID# 205515
-
-
New Jersey
-
Clifton, New Jersey, United States, 07012-1647
- Duplicate_Summit Medical Group /ID# 213863
-
Hackensack, New Jersey, United States, 07601-1997
- Skin Laser and Surgery Specialists of NY and NJ /ID# 206754
-
Hoboken, New Jersey, United States, 07030-2757
- Care Access Research /ID# 218476
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131-0001
- University of New Mexico School of Medicine /ID# 206756
-
-
New York
-
Bronx, New York, United States, 10458-5046
- Fordham Dermatology /ID# 218508
-
-
North Carolina
-
Wilmington, North Carolina, United States, 28401
- PMG Research of Wilmington LLC /ID# 205968
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Case Medical Center /ID# 206639
-
Marion, Ohio, United States, 43302-6225
- Awasty Research Network, LLC /ID# 206748
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74132
- Southside Dermatology /ID# 214451
-
Tulsa, Oklahoma, United States, 74136-7049
- Vital Prospects Clinical Research Institute, PC /ID# 205824
-
-
Oregon
-
Gresham, Oregon, United States, 97030-8316
- Cyn3rgy Research /ID# 218064
-
Medford, Oregon, United States, 97504
- Velocity Clinical Research Hallandale Beach /ID# 207544
-
-
Tennessee
-
Jackson, Tennessee, United States, 38305-2163
- Clinical Research Solutions, LLC /ID# 218416
-
Murfreesboro, Tennessee, United States, 37129-3194
- Stones River Dermatology /ID# 205178
-
-
Texas
-
Arlington, Texas, United States, 76014-3105
- Metroplex Dermatology /ID# 213307
-
Bellaire, Texas, United States, 77401
- Bellaire Dermatology /ID# 205470
-
Cypress, Texas, United States, 77433
- Center for Clinical Studies /ID# 213186
-
Dallas, Texas, United States, 75230
- Dermatology Treatment and Research Center, PA /ID# 205473
-
Fort Worth, Texas, United States, 76244-6548
- Epiphany Dermatology - Fort Worth /ID# 210073
-
Lewisville, Texas, United States, 75067
- Styde Research, LLC /ID# 213469
-
Pflugerville, Texas, United States, 78660
- Austin Institute for Clinical Research /ID# 206640
-
San Antonio, Texas, United States, 78229
- Derm Clin Res Ctr San Antonio /ID# 205469
-
-
Utah
-
Murray, Utah, United States, 84123-5632
- EPIC Medical Research /ID# 206382
-
Orem, Utah, United States, 84058
- Aspen Clinical Research /ID# 208399
-
-
Vermont
-
South Burlington, Vermont, United States, 05403-7204
- Timber Lane Allergy & Asthma Research, LLC /ID# 206897
-
-
Virginia
-
Lynchburg, Virginia, United States, 24501-1403
- The Education & Research Foundation, Inc. /ID# 206900
-
-
Washington
-
Bellingham, Washington, United States, 98225-1945
- Bellingham Asthma Allergy and Immunology Clinic /ID# 210357
-
-
Wisconsin
-
Kenosha, Wisconsin, United States, 53144-1782
- Clinical Investigation Specialist, Inc - Kenosha /ID# 215933
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and < 18 years of age
- Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria
- Active moderate to severe AD defined by Eczema Area and Severity Index (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, body surface area (BSA) affected by AD ≥ 10%, and weekly average of daily Worst Pruritus numerical rating scale (NRS) score ≥ 4.
- Candidate for systemic therapy or have recently required systemic therapy for AD
- Documented history (within 6 months prior to Baseline) of inadequate response to topical corticosteroid (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD or for whom topical treatments are otherwise medically inadvisable due to side effects or safety risks
Exclusion Criteria:
- Prior exposure to any Janus kinase (JAK) inhibitor
- Unable or unwilling to discontinue current AD treatments prior to the study
- Requirement of prohibited medications during the study
- Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
- Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo / Upadacitinib
Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period.
At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
|
Tablets taken orally once a day
Tablets taken orally once a day
Other Names:
|
Experimental: Upadacitinib 15 mg QD
Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
|
Tablets taken orally once a day
Other Names:
|
Experimental: Upadacitinib 30 mg QD
Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
|
Tablets taken orally once a day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
Time Frame: Baseline and Week 16
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. |
Baseline and Week 16
|
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
Time Frame: Baseline and Week 16
|
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale:
|
Baseline and Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
Time Frame: Baseline and Week 16
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. |
Baseline and Week 16
|
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
Time Frame: Baseline and Week 2
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score. |
Baseline and Week 2
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3
Time Frame: Baseline and Day 3
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement in Worst Pruritus NRS score from Baseline at Day 3 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 15 mg group versus placebo group only. |
Baseline and Day 3
|
Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
Time Frame: From first dose of study drug to Week 16
|
A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication.
Flare was assessed in participants with an EASI score of 65.4 or less at Baseline.
|
From first dose of study drug to Week 16
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
|
The ADerm-IS is a 10-item patient reported outcome (PRO) questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12. |
Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
|
The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period.
For the skin pain item participants were asked on a daily basis to indicate how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain).
The ADerm-SS skin pain score was analyzed using weekly rolling averages of daily scores.
The minimal clinically important difference for ADerm-SS skin pain score is 4.
|
Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16
Time Frame: Baseline and Week 16
|
The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period.
The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable).
The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly).
The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms.
The minimal clinically important difference for ADerm-SS TSS-7 is 28.
|
Baseline and Week 16
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
Time Frame: Baseline and Week 16
|
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items [Items 8-10] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11. |
Baseline and Week 16
|
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
Time Frame: Baseline and Week 16
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. |
Baseline and Week 16
|
Main Study: Percent Change From Baseline in EASI Score at Week 16
Time Frame: Baseline and Week 16
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1)] moderate [2], or severe [3]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement. |
Baseline and Week 16
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
Time Frame: Baseline and Week 16
|
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit. |
Baseline and Week 16
|
Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16
Time Frame: Baseline and Week 16
|
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis).
The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%).
The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20).
SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).
A negative change from Baseline indicates improvement.
|
Baseline and Week 16
|
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16
Time Frame: Baseline and Week 16
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score. |
Baseline and Week 16
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
|
Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16
Time Frame: Baseline and Week 16
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score. |
Baseline and Week 16
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 4
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
|
Baseline (last available rolling average before the first dose of study drug) and Week 4
|
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2
Time Frame: Baseline and Week 2
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score. |
Baseline and Week 2
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 1
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
|
Baseline (last available rolling average before the first dose of study drug) and Week 1
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2
Time Frame: Baseline and Day 2
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
|
Baseline and Day 2
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3
Time Frame: Baseline and Day 3
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
|
Baseline and Day 3
|
Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
Time Frame: From first dose of study drug to Week 16
|
A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication.
Flares were assessed in participants with an EASI score of 65.4 or less at Baseline.
|
From first dose of study drug to Week 16
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
|
The ADerm-IS is a 10-item patient reported outcome questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12. |
Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16
Time Frame: Baseline and Week 16
|
The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period.
The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable).
The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly).
The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms.
The minimal clinically important difference for ADerm-SS TSS-7 is 28.
|
Baseline and Week 16
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
Time Frame: Baseline and Week 16
|
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items [Items 8-10] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11. |
Baseline and Week 16
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16
Time Frame: Baseline and Week 16
|
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14. |
Baseline and Week 16
|
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16
Time Frame: Baseline and Week 16
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score. |
Baseline and Week 16
|
Adolescents: Percent Change From Baseline in EASI Score at Week 16
Time Frame: Baseline and Week 16
|
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1)] moderate [2], or severe [3]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement. |
Baseline and Week 16
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16
Time Frame: Baseline and Week 16
|
The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults.
Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days.
Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema).
A change in POEM score of 3.4 points is considered the minimal clinically important difference.
|
Baseline and Week 16
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16
Time Frame: Baseline and Week 16
|
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit. |
Baseline and Week 16
|
Adolescents: Percent Change From Baseline in SCORAD Score at Week 16
Time Frame: Baseline and Week 16
|
SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis).
The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%).
The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20).
SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst).
A negative change from Baseline indicates improvement.
|
Baseline and Week 16
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
|
Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 4
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
|
Baseline (last available rolling average before the first dose of study drug) and Week 4
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 1
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
|
Baseline (last available rolling average before the first dose of study drug) and Week 1
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2
Time Frame: Baseline and Day 2
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11- point scale from 0 (no itch) to 10 (worst imaginable itch).
The percentage of participants who had a 4-point or greater improvement from Baseline in Worst Pruritus NRS score at Day 2 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 30 mg group versus placebo group only.
|
Baseline and Day 2
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16
Time Frame: Baseline and Week 16
|
The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS Daily Activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14. |
Baseline and Week 16
|
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
A negative change from Baseline indicates improvement.
|
Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16
Time Frame: Baseline and Week 16
|
The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference. |
Baseline and Week 16
|
Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16
Time Frame: Week 16
|
The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D).
Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress.
For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.
|
Week 16
|
Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
Time Frame: Week 16
|
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. The DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit. |
Week 16
|
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
Time Frame: Baseline and Week 16
|
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale:
|
Baseline and Week 16
|
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
|
The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked to indicate on a daily basis how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The minimal clinically important difference for ADerm-SS skin pain score is 4. The ADerm-SS skin pain score was analyzed based on weekly rolling averages of daily scores. |
Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Time Frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
A negative change from Baseline indicates improvement.
|
Baseline (last available rolling average before the first dose of study drug) and Week 16
|
Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16
Time Frame: Week 16
|
The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D).
Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress.
For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.
|
Week 16
|
Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
Time Frame: Week 16
|
The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit. |
Week 16
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Publications and helpful links
General Publications
- Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15.
- Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.
- Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaci D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21. Erratum In: Lancet. 2021 Jun 5;397(10290):2150.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Hypersensitivity
- Skin Diseases, Eczematous
- Dermatitis
- Eczema
- Dermatitis, Atopic
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Protein Kinase Inhibitors
- Janus Kinase Inhibitors
- Upadacitinib
Other Study ID Numbers
- M18-891
- 2022-502936-38-00 (Other Identifier: EU CT)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Placebo for Upadacitinib
-
AbbVieTerminatedRheumatoid Arthritis (RA)Belgium, Canada, Czechia, Hungary, Poland, Spain, United Kingdom
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
-
AbbVieCompletedSystemic Lupus Erythematosus (SLE)United States, Argentina, Australia, Bulgaria, Canada, China, Colombia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom
-
AbbVieCompletedSystemic Lupus Erythematosus (SLE)United States, Argentina, Australia, Bulgaria, China, Colombia, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom
-
AbbVieCompletedRheumatoid Arthritis (RA)United States, Belgium, Canada, Czechia, Hungary, Poland, Puerto Rico, Spain, United Kingdom
-
AbbVieActive, not recruitingRheumatoid ArthritisUnited States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, ... and more
-
AbbVieActive, not recruitingAtopic DermatitisUnited States, Argentina, Australia, Bosnia and Herzegovina, Bulgaria, Canada, China, Colombia, Croatia, Denmark, Estonia, Finland, France, Germany, Italy, Japan, Malaysia, New Zealand, Puerto Rico, Romania, Russian Federation, Sw... and more
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
-
AbbVieWithdrawn
-
AbbVieActive, not recruitingCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more